NCT04333082 (RESET) is a clinical trial of Data collection in Status Epilepticus, sponsored by University Hospital, Basel, Switzerland.

Who is sponsoring NCT04333082?

NCT04333082 is sponsored by University Hospital, Basel, Switzerland.

What drugs are being tested in NCT04333082?

Interventions in NCT04333082: Data collection.

What condition does NCT04333082 study?

NCT04333082 studies Status Epilepticus, Refractory Status Epilepticus.

Is NCT04333082 still recruiting?

NCT04333082 is currently completed. Last updated 26 February 2024.

Last reviewed 2024-02-26 · How we verify

NCT04333082: RESET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Refractory Status Epilepticus Treatment: Quality and Efficacy of Coma Induction

Completed Last updated 26 February 2024

What this trial tests

trial testing Data collection in Status Epilepticus in 147 participants. Completed in 3 August 2022.

Timeline

22 April 2020

Primary endpoint
15 August 2021

3 August 2022

Quick facts

Lead sponsor	University Hospital, Basel, Switzerland
Status	Completed
Study type	OBSERVATIONAL
Enrollment	147
Start date	22 April 2020
Primary completion	15 August 2021
Estimated completion	3 August 2022
Sites	1 location across Switzerland

Drugs / interventions tested

Data collection — full drug profile →

Conditions studied

Status Epilepticus — all drugs for Status Epilepticus →
Refractory Status Epilepticus — all drugs for Refractory Status Epilepticus →

Sponsor

University Hospital, Basel, Switzerland

Who can join

18 and older, any sex, with Status Epilepticus or Refractory Status Epilepticus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to investigate the effects of different treatment characteristics regarding the use of intravenous anesthetic drugs (IVADs) as a rescue treatment for refractory Status epilepticus (RSE) on course and outcome. A retrospective data extraction from the digital medical records, the electroencephalographic and microbiologic database of all consecutive adult patients with Status epilepticus (SE) admitted to the University Hospital Basel is undertaken.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Association Between Induced Burst Suppression and Clinical Outcomes in Patients With Refractory Status Epilepticus: A 9-Year Cohort Study.
Fisch U, Jünger AL, Baumann SM, Semmlack S, et al · · 2023 · cited 27× · PMID 36889924 · DOI 10.1212/wnl.0000000000207129

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

NCT07010562 — A Multi-site, Pre-clinical, Prospective Data Collection Study in Patients Undergoing a Right Heart Catheterization · not yet recruiting
NCT07418359 — Comparison of Patient's Physical Activity Levels According to the Physical Activity Level of Their General Practitioner · recruiting
NCT07197398 — Preoperative Data and the Spinal Spread of Local Anesthetic in Cesarean Section · recruiting
NCT06998797 — Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study · not yet recruiting
NCT07529730 — Outcomes of Surgical Treatment in Patients With Infective Endocarditis · completed

Other recruiting trials for Status Epilepticus

Currently open trials in the same condition.

NCT06401707 — PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest · Phase 2 · recruiting
NCT06194747 — Improving Status Epilepticus Treatment Times · NA · recruiting
NCT06017973 — The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus · NA · recruiting
NCT05851391 — buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest · Phase 2 · recruiting
NCT05839418 — Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status · recruiting

Other University Hospital, Basel, Switzerland trials

Trials by the same sponsor.

NCT07444788 — Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants · Phase 1 · recruiting
NCT07494214 — Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants · Phase 1 · recruiting
NCT07419048 — Artificial Intelligence or Human Hand? Evaluating Inferior Vena Cava Imaging for Hydration Status · recruiting
NCT06978777 — Effect of Caffeine on Cold-stimulated Brown Adipose Tissue Activity · NA · recruiting
NCT07273630 — Effect of Protein Supplementation and Fluid Restriction on Plasma Sodium Levels in Patients Undergoing Pituitary Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04333082 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Basel, Switzerland
Last refreshed: 26 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04333082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing